Azzad Asset Management’s Ionis Pharmaceuticals IONS Stock Holding History

Azzad Asset Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-8,451	Closed	-$436K	–	310
2018 Q3	$436K	Hold	8,451	–	–	0.12%	255
2018 Q2	$352K	Buy	8,451 +664	+9%	+$29.4K	0.1%	269
2018 Q1	$343K	Buy	7,787 +400	+5%	+$20.3K	0.1%	257
2017 Q4	$372K	Hold	7,387	–	–	0.12%	241
2017 Q3	$375K	Hold	7,387	–	–	0.13%	234
2017 Q2	$376K	Buy	+7,387	New	+$344K	0.13%	226

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Azzad Asset Management's IONS Position: Q4 2018 in Review

Azzad Asset Management sold out of Ionis Pharmaceuticals (IONS) in Q4 2018, closing a stake of 8,451 shares — an estimated $436K sold.

Azzad Asset Management first reported a position in IONS in Q2 2017 and held it in 6 quarters. The position peaked at $436K in Q3 2018. 329 funds tracked by Wall St. Rank hold IONS as of Q4 2018.

Azzad Asset Management reported no remaining Ionis Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Azzad Asset Management sold 8,451 Ionis Pharmaceuticals shares in Q4 2018, an estimated $436K.
Azzad Asset Management first reported a position in Ionis Pharmaceuticals in Q2 2017 and held it in 6 quarters.
Azzad Asset Management's Ionis Pharmaceuticals position peaked at $436K in Q3 2018.
329 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2018.

Based on Azzad Asset Management's 13F filing for Q4 2018, filed 1 Apr 2024.